XORTX Therapeutics Inc Cash Flow Conversion Efficiency
XORTX Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, XORTX Therapeutics Inc (XRTX) has a cash flow conversion efficiency ratio of -0.319x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-629.62K ≈ $-455.46K USD) by net assets (CA$1.97 Million ≈ $1.43 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of XORTX Therapeutics Inc (2018–2024)
Cash flow conversion efficiency of XORTX Therapeutics Inc from 2018 to 2024. This chart illustrates how XORTX Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View XORTX Therapeutics Inc stock price for real-time trading data and today's change.
XORTX Therapeutics Inc Cash Flow Conversion Ratio Explained
XORTX Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
XORTX Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of XORTX Therapeutics Inc ranked by their cash flow conversion efficiency. Also see XORTX Therapeutics Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Oriental Trimex Limited
NSE:ORIENTALTL
|
0.008x |
|
Technoplus Ventures Ltd
TA:TNPV
|
-0.040x |
|
Maxeon Solar Technologies Ltd
NASDAQ:MAXN
|
0.148x |
|
ScandiDos AB
ST:SDOS
|
-0.020x |
|
BELLUSCURA PLC LS -01
F:9VQ
|
N/A |
|
NR 21 S.A.
PA:NR21
|
-0.008x |
|
Megapower Makmur TBK PT
JK:MPOW
|
0.022x |
|
Capricorn Energy PLC
LSE:CNE
|
0.335x |
Annual Cash Flow Conversion Efficiency for XORTX Therapeutics Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of XORTX Therapeutics Inc from 2018 to 2024. Review XORTX Therapeutics Inc (XRTX) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CA$3.34 Million ≈ $2.41 Million |
CA$-3.68 Million ≈ $-2.66 Million |
-1.103x | +22.26% |
| 2023-12-31 | CA$4.64 Million ≈ $3.36 Million |
CA$-6.58 Million ≈ $-4.76 Million |
-1.418x | +17.35% |
| 2022-12-31 | CA$6.97 Million ≈ $5.05 Million |
CA$-11.97 Million ≈ $-8.66 Million |
-1.716x | -373.73% |
| 2021-12-31 | CA$16.74 Million ≈ $12.11 Million |
CA$-6.06 Million ≈ $-4.39 Million |
-0.362x | +37.53% |
| 2020-12-31 | CA$1.26 Million ≈ $908.75K |
CA$-728.40K ≈ $-526.91K |
-0.580x | -149.19% |
| 2019-12-31 | CA$-211.72K ≈ $-153.16K |
CA$-249.58K ≈ $-180.54K |
1.179x | +124.37% |
| 2018-12-31 | CA$321.54K ≈ $232.60K |
CA$-1.56 Million ≈ $-1.13 Million |
-4.837x | -- |
About XORTX Therapeutics Inc
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the … Read more